Assessment of Serum Atherogenic Indices and Insulin Resistance in Retinal Vein Occlusion

Şaban Gönül; Serhat Eker

doi:10.4274/tjo.galenos.2024.66367

ABSTRACT

Objectives:

This study aimed to investigate serum atherogenic indices as novel cardiovascular risk factors associated with retinal vein occlusion (RVO).

Materials and Methods:

This retrospective case-control study included 57 patients with newly diagnosed RVO whose plasma lipid profile (low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], total cholesterol [TC], and triglycerides [TG]) and insulin resistance were examined. Serum atherogenic indices (LDL-C/HDL-C, TC/HDL-C, TG/HDL-C, and non-HDL-C/HDL-C ratios) and presence of insulin resistance were compared between the patients and 63 healthy subjects. Cut-off values were determined by receiver operating characteristic curve analysis.

Results:

The mean age of the RVO patients was 63.7±9.4 years. Plasma levels of LDL-C, HDL-C, TC, and TG showed no significant difference between the patient and control groups (p>0.05). However, LDL-C/HDL-C, non-HDL-C/HDL-C, and TC/HDL-C ratios were higher in the RVO group compared to healthy subjects (p=0.015, p=0.036, and p=0.015, respectively). Fasting insulin concentrations, plasma insulin, and homeostasis model assessment of insulin resistance (HOMA-IR) index were higher in the RVO patients compared to controls (p=0.003, p=0.001, and p=0.001, respectively).

Conclusion:

LDL-C/HDL-C, TC/HDL-C, and non-HDL-C/HDL-C ratios were found to be increased in RVO. Compared to the traditional plasma lipid profile, serum atherogenic indices were found to be superior predictors of RVO development. Measurement of HOMA-IR index should be taken into consideration in the evaluation of insulin resistance. High serum atherogenic indexes in RVO patients reveal the need to take precautions against the risk of cardiovascular disease and stroke.

Keywords:

Retinal vein occlusion, serum atherogenic index, serum lipid profile, insulin resistance, HOMA-IR

Introduction

Retinal vein occlusion (RVO) is a common retinal vascular disease that can lead to visual impairment.¹ The prevalence of RVO has been reported as between 0.3% and 1.6%.^1,2 Its relatively high prevalence warrants attention to the prevention and management of the disease. Although there is still uncertainty regarding the pathogenesis of RVO, comprehensive studies have found an increased risk in patients with cardiovascular diseases such as arterial hypertension, hypercholesterolemia, atherosclerosis, and diabetes mellitus (DM).³ Other identified risk factors for RVO development include aging, smoking, obesity, insulin resistance, trauma, open-angle glaucoma, thrombophilia, and hyperviscosity.^4,5,6

The clinical signs of RVO include disseminated superficial and deep retinal hemorrhages, retinal edema, venous dilation, venous sheathing, anastomotic vessels, intraretinal microvascular disturbances, optic disc hyperemia, and optic disc edema. According to the location and findings of the affected vein, RVO is divided into the subtypes of branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).^7,8 Visual symptoms and prognosis rely on the subtype of RVO and the degree of macular involvement.

The significant relationship with cardiovascular risk factors necessitates a systemic evaluation including assessment of blood pressure, complete blood count, lipid profile, glucose metabolism, and insulin resistance for all patients with RVO during the diagnosis and treatment process. Regarding the traditional fasting plasma lipid profile (triglycerides [TG], total cholesterol [TC], low-density lipoprotein cholesterol [LDL-C], and high-density lipoprotein cholesterol [HDL-C]), the relationship between these parameters and RVO is well-established in the literature.^{2,5,7,9,10,11,12} The use of lipid ratios allows assessment of both antiatherogenic and atherogenic lipid parameters.¹³ There are previous studies evaluating these ratios as novel biomarkers in cardiovascular diseases. However, according to our knowledge based on a review of the literature, no comprehensive study has evaluated TG/HDL-C, LDL-C/HDL-C, TC/HDL-C, and non-HDL-C/HDL-C ratios in patients with RVO. The purpose of this study was to investigate serum atherogenic indices as novel cardiovascular risk factors associated with RVO and contribute to the overall health status of patients with RVO.

Materials and Methods

Results

There were 57 RVO patients with a mean age of 63.7±9.4 years. The healthy control group included 63 individuals with a mean age of 62.2±5.7 years. The age and sex distribution of the individuals in the groups did not differ significantly (p>0.05). While the frequency of HT differed significantly between the patient group and the control group (p=0.011), there was no difference in the frequency of DM (p>0.05). The demographic data of the subjects are summarized in Table 1.

Serum TG, TC, LDL-C, and HDL-C showed no statistical differences between the groups (p>0.05). Non-HDL-C was higher in the RVO group (p=0.042). In addition, LDL-C/HDL-C, TC/HDL-C, and non-HDL-C/HDL-C ratios were also higher in RVO patients compared to healthy subjects (p=0.036, p=0.015, and p=0.015, respectively). On the other hand, TG/HDL-C ratio showed no significant difference (p>0.05). Correlation analysis revealed that TG/HDL-C was correlated with FPG (r=0.211, p=0.021), insulin (r=0.308, p=0.001), HbA1c (r=0.299, p=0.001), and HOMA-IR (r=0.317, p=0.0001). Details are given in Table 2.

Regarding glucose metabolism, the RVO group had higher fasting insulin concentrations, plasma insulin, and HOMA-IR index (p=0.003, p=0.001, and p=0.001, respectively). The proportion of subjects with insulin resistance (HOMA-IR ≥2.5) was significantly higher in RVO compared to controls (p=0.0001). However, mean HbA1c values did not differ significantly between the groups (p>0.05) (Table 2).

In subgroup analysis, 68.4% (n=39) of patients with RVO showed characteristics of BRVO, while 31.6% (n=18) of them had the presentation of CRVO. Of all the lipid and glucose metabolism parameters, only LDL-C differed significantly between subgroups. The frequency of HT was higher in CRVO (p=0.011). The characteristics of the CRVO and BRVO subgroups are shown in Table 3.

The Framingham 10-year risk in subjects with RVO was 10.8%, which was significantly greater than in the control group (p<0.05). Men in particular had significantly higher Framingham risk scores than women in the RVO group (p=0.0001). The mean score was 10.48% in BRVO patients and 11.75% in the CRVO group. Although patients with CRVO had higher Framingham 10-year risk, there was no significant difference between BRVO and CRVO subjects in analysis (p>0.05).

ROC curve analysis was performed to determine the specificity and sensitivity of atherogenic indices in differentiating RVO patients from controls, as well as cut-off values for predicting RVO, BRVO, and CRVO. According to our results, values higher than the following cut-off values were significant in terms of RVO risk: 4.44 for TC/HDL-C values (64% sensitivity, 65% specificity), 3.41 for non-HDL-C/HDL-C (64% sensitivity, 63% specificity), 2.64 for TG/HDL-C (68% sensitivity, 50% specificity), and 2.89 for LDL-C/HDL-C (63% sensitivity, 65% specificity). In addition, TC/HDL-C values >4.52 (72% sensitivity, 68% specificity) and LDL-C/HDL-C values greater than >2.9 (66% sensitivity, 68% specificity) were found to be significant in predicting CRVO. ROC curve analysis and the cut-off values for RVO, BRVO, and CRVO are shown in Table 4.

Discussion

RVO is the most common retinal vasculopathy following diabetic retinopathy and occurs due to disturbances of the retinal venous circulation.⁸ The most common known risk factors for cardiovascular comorbidities are also strongly associated with RVO. Previously, studies have investigated parameters associated with cardiovascular health in RVO.^{2,5,7,10,11,12,19} Khan et al.²⁰ stated that patients with RVO have an elevated 10-year Framingham risk score for cardiovascular disease. Furthermore, it has been emphasized that therapy aimed at controlling risk factors should be planned in these patients. Therefore, patients diagnosed with RVO should be examined in terms of cardiovascular health.

Dyslipidemia, presenting as elevated levels of TG, LDL-C, and TC and a low level of HDL-C, is a well-defined traditional risk factor for RVO.^5,11,12,20 However, it has been reported that lipoproteins and some of their ratios (TG/HDL-C, TC/HDL-C, LDL-C/HDL-C, and non-HDL-C/HDL-C) show a stronger statistical relationship with the severity and prevalence of coronary artery disease in determining the risk of atherosclerosis compared to measurements of lipid levels alone.²¹ The current study aimed to evaluate the serum lipid ratios and insulin resistance status of newly diagnosed RVO patients.

It is known that a high TG/HDL-C ratio is associated with abdominal obesity and insulin resistance, even with no change in LDL-C levels, as well as high BMI and hyperinsulinemia.^22,23,24 Furthermore, the TG/HDL-C ratio was reported to be a strong predictor of mortality and cardiovascular health in women with presumed myocardial ischemia.²⁵ In another large population survey of participants aged 20-90 years, an association was demonstrated between the TG/HDL-C ratio and cardiovascular disease.²⁶ Çelik and Gökçe²⁷ reported that RVO patients had a significantly higher atherogenic index of plasma (log [TG/HDL-C]) than the control group. This parameter was also reported to be related with metabolic-associated fatty liver disease and unfavorable prognosis of percutaneous coronary intervention.^28,29 In our study, the TG/HDL-C ratio was higher in the RVO group. However, no statistically significant difference was determined. Moreover, we observed that the TG/HDL-C ratio was correlated positively with HOMA-IR, insulin, HbA1c, and FPG. Therefore, this ratio should be evaluated together with glucose metabolism and insulin resistance markers. FPG, insulin, and HOMA-IR index were found to be increased in RVO patients compared to the control group. The average HbA1c value of the patients and healthy group was above 6%, and no statistical difference was found between the groups. In our study of RVO patients, TG/HDL-C ratio and HbA1c were not good indicators for the evaluation of insulin resistance. However, HOMA-IR index calculated with insulin level and FPG was found to be markedly higher in the RVO group. Therefore, we believe this is a crucial parameter that should be used in the evaluation of insulin resistance in subjects with RVO. In the literature, FPG with insulin level and HbA1c ratio have been previously evaluated in RVO patients.^9,30,31 As far as we know, the current study is the first in which the HOMA-IR index was applied in the assessment of insulin resistance in RVO patients.

Ratios of cholesterol ester-rich lipoprotein levels (LDL-C/HDL-C and TC/HDL-C) are among the well-known markers of ischemic heart disease, and elevated ratios indicate a disorder in cholesterol metabolism.^32,33 TC/HDL-C ratio is a parameter of coronary heart disease and includes both an atherogenic and an antiatherogenic lipid parameter.³⁴ Since the LDL-C level is determined based on TG, TC, and HDL-C concentrations, it cannot be calculated with traditional formulas in patients with a TG level of more than 399.¹⁴ In this case, direct evaluation of the TC/HDL-C ratio can provide information in terms of atherogenic lipid components. Earlier studies regarding serum lipid profiles in coronary heart disease patients indicated that TC/HDL-C ratios were high when compared to controls.^23,35,36 Stampfer et al.³³ demonstrated that a higher LDL/HDL ratio was associated with an elevated risk of myocardial infarction. In a 20-year prospective study of 3914 patients with stroke, low HDL-C and high TC/HDL-C ratio were emphasized to be related to the risk of total and ischemic stroke in male and female patients.³⁷ In our study, the TC/HDL-C ratio was higher in RVO patients than the healthy subjects. In their biochemical analysis of 60 patients with ischemic heart disease, Ghosh et al.³⁶ reported a TC/HDL-C ratio of 4.9±1.2, which was notably higher than the control group. We think that the high TC/HDL-C and LDL-C/HDL-C ratios in RVO patients suggest that these parameters may be associated with worse cardiovascular health status and clinical outcomes.

As is known, atherosclerosis is a crucial risk factor for RVO, and abnormalities in cholesterol metabolism also pose a threat.³ Previously, non-HDL-C has been reported to be a superior predictive marker of arterial vessel wall stiffness compared to LDL-C.³⁸ Therefore, the ratio of non-HDL-C/HDL-C is easy, convenient, and better for the assessment of coronary artery disease and arterial stiffness risk than lipid parameters alone.^39,40 In the current study, non-HDL-C levels and non-HDL-C/HDL-C ratios were observed to be increased in the RVO patients compared to the healthy subjects. This result undoubtedly reveals the necessity of further cardiovascular examination of patients diagnosed with RVO. Moreover, it demonstrates the importance of vascular health both in protecting the health of the fellow eye and in the recovery of the eye affected by RVO.

In subgroup analysis, the frequency of hypertension was higher in the group with CRVO, consistent with the literature.⁵ In terms of serum lipids, however, only LDL-C levels were found to be increased in the CRVO group. ROC analysis revealed that TC/HDL-C and LDL-C/HDL-C ratios were significant for predicting CRVO, while none of the ratios were significant for BRVO. The fact that TC/HDL-C and LDL-C/HDL-C ratios are indicative of CRVO may demonstrate a higher risk of cardiovascular disease. More comprehensive studies should be done on serum lipids and atherogenic indices to reveal the differences between CRVO and BRVO.

The Framingham risk score has been used for many years to estimate the 10-year risk of myocardial infarction or death in various populations.²⁰ In our study, the Framingham risk score was higher in RVO patients (10.8%), and especially in men. Similarly, a meta-analysis showed the 10-year Framingham risk score in subjects with RVO to be 10.1%.²⁰ In the current study, no significant difference was seen in the Framingham risk score between CRVO and BRVO patients. We attributed the slightly higher Framingham risk score in CRVO cases to the higher frequency of hypertension. In another study, higher 10-year risk of coronary heart disease was reported in BRVO patients due to the frequency of hypertension and other cardiovascular risk factors.⁴¹ In our study, there was intermediate risk of coronary events in both BRVO and CRVO. Although the Framingham risk score was not found to differ in CRVO cases, TC/HDL-C and LDL-C/HDL-C ratios were predictive of CRVO. As can be seen from these results, it is necessary to evaluate cardiovascular health status in RVO patients.

Conclusion

The current study showed that RVO was associated with increased ratios of TC/HDL-C, LDL-C/HDL-C and non-HDL-C/HDL-C compared to healthy subjects. The results suggest that measurement of HOMA-IR index should be considered in the evaluation of insulin resistance in RVO cases. These abnormalities may contribute to the pathogenesis of RVO and the associated risk of cardiovascular disease and stroke in these patients.

Study Limitations

To the best of our knowledge, the current study is the first to evaluate serum lipid ratios as serum atherogenic indices and the HOMA-IR index in patients with RVO. However, the study had some limitations. The small sample size and single-center design are the most important of them. Additionally, the study may have biased because the sample consisted of subjects presenting for care. Finally, causality between dyslipidemia and RVO cannot be established because of the cross-sectional study design. Future research should focus on the effect of changes in serum lipid ratios on the recovery process by examining the outcomes of RVO treatment in prospective cohort studies.

References

z Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY; International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117:313-319.

Wong TY, Larsen EK, Klein R, Mitchell P, Couper DJ, Klein BE, Hubbard LD, Siscovick DS, Sharrett AR. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies. Ophthalmology. 2005;112:540-547.

Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol. 2001;131:61-77.

Prisco D, Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb. 2002;32:308-311.

O’Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol. 2008;126:692-699.

DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.

Cheung N, Klein R, Wang JJ, Cotch MF, Islam AF, Klein BE, Cushman M, Wong TY. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Invest Ophthalmol Vis Sci. 2008;49:4297-4302.

Ip M, Hendrick A. Retinal Vein Occlusion Review. Asia Pac J Ophthalmol (Phila). 2018;7:40-45.

Ogawa O, Onuma T, Uchino H, Takayanagi Y, Tanaka Y, Yamasaki Y, Atsumi Y, Matsuoka K, Kawamori R. Insulin resistance and atherosclerosis in branch retinal vein occlusion. Jpn J Ophthalmol. 2003;47:351-355.

Wu CY, Riangwiwat T, Limpruttidham N, Rattanawong P, Rosen RB, Deobhakta A. Association of retinal vein occlusion with cardiovascular events and mortality: A systematic review and meta-analysis. Retina. 2019;39:1635-1645.

Kim J, Lim DH, Han K, Kang SW, Ham DI, Kim SJ, Chung TY. Retinal Vein Occlusion is Associated with Low Blood High-Density Lipoprotein Cholesterol: A Nationwide Cohort Study. Am J Ophthalmol. 2019;205:35-42.

Dodson PM, Galton DJ, Hamilton AM, Blach RK. Retinal vein occlusion and the prevalence of lipoprotein abnormalities. Br J Ophthalmol. 1982;66:161-164.

Jia L, Long S, Fu M, Yan B, Tian Y, Xu Y, Gou L. Relationship between total cholesterol/high-density lipoprotein cholesterol ratio, triglyceride/high-density lipoprotein cholesterol ratio, and high-density lipoprotein subclasses. Metabolism. 2006;55:1141-1148.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.

Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.

Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol. 1976;38:46-51.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.

Gutch M, Kumar S, Razi SM, Gupta KK, Gupta A. Assessment of insulin sensitivity/resistance. Indian J Endocrinol Metab. 2015;19:160-164.

Bucciarelli P, Passamonti SM, Gianniello F, Artoni A, Martinelli I. Thrombophilic and cardiovascular risk factors for retinal vein occlusion. Eur J Intern Med. 2017;44:44-48.

Khan Z, Almeida DR, Rahim K, Belliveau MJ, Bona M, Gale J. 10-Year Framingham risk in patients with retinal vein occlusion: a systematic review and meta-analysis. Can J Ophthalmol. 2013;48:40-45.

Naito HK. The association of serum lipids, lipoproteins, and apolipoproteins with coronary artery disease assessed by coronary arteriography. Ann N Y Acad Sci. 1985;454:230-238.

Lamarche B, Després JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ. Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Québec cardiovascular study. Atherosclerosis. 1996;119:235-245.

Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, Dagenais GR, Després JP. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med. 2001;161:2685-2692.

Lamarche B, Tchernof A, Mauriège P, Cantin B, Dagenais GR, Lupien PJ, Després JP. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA. 1998;279:1955-1961.

Bittner V, Johnson BD, Zineh I, Rogers WJ, Vido D, Marroquin OC, Bairey-Merz CN, Sopko G. The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women’s Ischemia Syndrome Evaluation (WISE). Am Heart J. 2009;157:548-555.

Vega GL, Barlow CE, Grundy SM, Leonard D, DeFina LF. Triglyceride-to-high-density-lipoprotein-cholesterol ratio is an index of heart disease mortality and of incidence of type 2 diabetes mellitus in men. J Investig Med. 2014;62:345-349.

Çelik A, Gökçe SE. Atherogenicindex of plasma (AIP) as a novel biomarker to predict retinal vein occlusion. Hitit Medical Journal. 2024;6:79-84.

Samimi S, Rajabzadeh S, Rabizadeh S, Nakhjavani M, Nakhaei P, Avanaki FA, Esteghamati A. Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes. Eur J Med Res. 2022;27:112.

Qin Z, Zhou K, Li Y, Cheng W, Wang Z, Wang J, Gao F, Yang L, Xu Y, Wu Y, He H, Zhou Y. The atherogenic index of plasma plays an important role in predicting the prognosis of type 2 diabetic subjects undergoing percutaneous coronary intervention: results from an observational cohort study in China. Cardiovasc Diabetol. 2020;19:23.

Shahsuvaryan ML, Melkonyan AK. Central retinal vein occlusion risk profile: a case-control study. Eur J Ophthalmol. 2003;13:445-452.

Cugati S, Wang JJ, Knudtson MD, Rochtchina E, Klein R, Klein BE, Wong TY, Mitchell P. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology. 2007;114:520-524.

Rapaport E, Bilheimer DW, Chobanian AV, Hajjar DP, Hawkins CM, Hutchins GM, Kris-Etherton PM, Luepker RV, McIntosh HD, Pepine CJ, Pettinger WA, Schonfeld G, Tulcin DF, Criqui MH, Gordon DJ, Austin MA, Assmann G, Heiss G, Bush TL, Paoletti R, Rudel LL, Havel RJ, Tall A, Ginsberg HN, Bradley WA, Brewer Jr B, Brunzell JD, LaRosa JC, Rossouw JE, Huttunen JK, Bachorik PS, Castelli WP, Hulley SB, Chait A, Denke MA, Wood PD, Gotto Jr AM, Schaefer EJ, Lewis B. Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA. 1993;269:505-510.

Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.

Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med. 1994;121:641-647.

Achari V, Thakur AK. Association of major modifiable risk factors among patients with coronary artery disease--a retrospective analysis. J Assoc Physicians India. 2004;52:103-108.

Ghosh J, Mishra TK, Rao YN, Aggarwal SK. Oxidised LDL, HDL cholesterol, LDL cholesterol levels in patients of coronary artery disease. Indian J Clin Biochem. 2006;21:181-184.

Zhang Y, Tuomilehto J, Jousilahti P, Wang Y, Antikainen R, Hu G. Total and high-density lipoprotein cholesterol and stroke risk. Stroke. 2012;43:1768-1774.

Holewijn S, den Heijer M, Swinkels DW, Stalenhoef AF, de Graaf J. Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk. J Intern Med. 2010;268:567-577.

Kim SW, Jee JH, Kim HJ, Jin SM, Suh S, Bae JC, Kim SW, Chung JH, Min YK, Lee MS, Lee MK, Kim KW, Kim JH. Non-HDL-cholesterol/HDL-cholesterol is a better predictor of metabolic syndrome and insulin resistance than apolipoprotein B/apolipoprotein A1. Int J Cardiol. 2013;168:2678-2683.

Bittner V, Hardison R, Kelsey SF, Weiner BH, Jacobs AK, Sopko G; Bypass Angioplasty Revascularization Investigation. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 2002;106:2537-2542.

Martin SC, Butcher A, Martin N, Farmer J, Dobson PM, Bartlett WA, Jones AF. Cardiovascular risk assessment in patients with retinal vein occlusion. Br J Ophthalmol. 2002;86:774-776.